Rakovina Therapeutics Inc (RKV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has a cash flow conversion efficiency ratio of -0.548x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.04 Million ≈ $-748.85K USD) by net assets (CA$1.89 Million ≈ $1.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Rakovina Therapeutics Inc (RKV) market capitalisation for the company's overall valuation and market capitalisation.
Rakovina Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Rakovina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rakovina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rakovina Therapeutics Inc ranked by their cash flow conversion efficiency. See Rakovina Therapeutics Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TT Electronics Plc
LSE:TTG
|
0.041x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
-3.096x |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
The Scottish Oriental Smaller Companies Trust plc
LSE:SST
|
0.012x |
|
S4 Capital PLC
LSE:SFOR
|
0.039x |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
-0.056x |
|
Mittal Life Style Limited
NSE:MITTAL
|
0.102x |
Annual Cash Flow Conversion Efficiency for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Rakovina Therapeutics Inc from 2021 to 2024. View current stock price of Rakovina Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-3.86 Million ≈ $-2.79 Million |
-0.897x | -76.29% |
| 2023-12-31 | CA$3.66 Million ≈ $2.65 Million |
CA$-1.86 Million ≈ $-1.35 Million |
-0.509x | -59.59% |
| 2022-12-31 | CA$6.01 Million ≈ $4.35 Million |
CA$-1.92 Million ≈ $-1.39 Million |
-0.319x | -17.99% |
| 2021-12-31 | CA$8.54 Million ≈ $6.18 Million |
CA$-2.31 Million ≈ $-1.67 Million |
-0.270x | -- |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more